Optimal production and purification of n.c.a.Pr as a promising palliative agent for the treatment of metastatic bone pain.

This study proposes the beta-emitting radioisotope Pr as a promising candidate for palliative treatment of metastatic bone pain due to its desirable physical decay characteristics. An optimized process was developed for the production and purification of non-carrier-added Pr using a medium flux research reactor. Calculations were performed to determine the optimal irradiation time and cooling period for irradiating 1 mg of natural cerium oxide to indirectly produce Pr through the decay of Ce.

Evaluation of Re- IBA as a novel radiopharmaceutical for bone marrow ablation.

In this study, Ibandronate as a third generation of bisphosphonates was labeled with rhenium-188 radionuclide. Production and quality control of Re-IBA radiopharmaceutical was investigated. The radiation absorbed dose of this radiopharmaceutical was evaluated for adult male based on biodistribution data in mice using the RADAR and Sparks and Aydogan methodologies.

Estimation of Human Absorbed Dose of Re-Hynic-Bombesin Based on Biodistribution Data in Rats.

Background: HYNIC-Bombesin (BBN) is a potential peptide for targeted radionuclide therapy in gastrin-releasing peptide receptor (GRPr)-positive malignancies. The Re-HYNICBBN is a promising radiopharmaceutical for use in prostate cancer therapy.

Objective: The aim of this study was to estimate the absorbed dose due to Re-HYNIC-BBN radio-complex in human organs based on bio-distribution data of rats.

Human Absorbed Dose Evaluation of [177Lu]Lu-IBA as a Bone Palliative Candidate.

The role of lutetium-177 among bone-seeking radionuclides in targeted therapy is noteworthy. The clinical pharmacokinetics of ibandronate (IBA) indicates that this bisphonate has powerful bone mineral affinity. The aim of this study was to evaluate of [Lu]Lu-IBA efficacy as a new compound.

ESTIMATION OF HUMAN DOSE OF 188/186RE-HEDP COCKTAIL BASED ON OLINDA/EXM AND DISTRIBUTION DATA IN RATS.

188Re and 186Re are two applicable rhenium medical radioisotopes with complementary features that make them beneficial for different sizes of tumours. The aim of this study is to investigate 188/186Re-HEDP efficacy as a cocktail by calculating absorbed radiation dose in human organs based on biodistribution data obtained by injecting it to normal rats. Three rats were sacrificed at different time intervals and the percentage of injected dose per gram of each organ was measured by direct counting from rat data.

An analytical study of effect of the cell proliferation, half-life, and energy of radionuclides in targeted radiotherapy.

Aim: The treatment of the cancers is one of the most important challenges of nuclear medicine. Using targeted radiotherapy has increased the hope for the cure of the cancers. In the targeted radiotherapy, proliferations of tumor cells during radiotherapy are believed to be main reasons of treatment defeat.

Developing a new target design for producing Mo in a MTR reactor.

Mo is an important radioisotope and mainly produced using uranium fission reaction in a nuclear reactor. Investigation for probable improvements, especially on target geometry and in-core location of target is the main goal of this research. This is for producing more efficient of Mo in a typical Material Testing Reactors (MTRs).